Optibrium appoints Ian Smith as Chief Technology Officer – Cambridge Network

23 November 2022
As CTO, Ian will lead the Software Engineering, DevOps and Quality Assurance teams, driving the scale-up of the Company’s infrastructure and managing the expanding portfolio of products and development projects.
Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company. With over 25 years of biopharma experience, Ian will oversee the development of the Company’s technology portfolio and cloud services and guide the team’s growth to support the continued expansion of the Company’s global customer base. This latest hire marks a key milestone for Optibrium as it enters the next phase of commercial growth as a provider of innovative computational and AI drug discovery technologies.
Ian joins Optibrium having previously served as Head of Technology and Delivery for an insurance technology start-up, Hx—part of the Howden Group—where he developed innovative data, analytics and digital application-focused strategies through cloud platform delivery, as well as defining a target operating model to implement the Group’s data transformation and growth objectives. Prior to this, Ian worked at Merck, Sharp and Dohme (MSD), holding positions including Director of Research and Development Analytics, Director of IT Productivity and Director of Scientific Modelling & Real-World Data. During his tenure as Director R&D Analytics, Ian led a team to define, develop and execute an 18-month strategy to build Merck’s next-generation machine learning and AI-driven analytics platform and data science capabilities to mature research and develop scientific insights.
Ian Smith, Chief Technology Officer, Optibrium, commented: “I’m excited to join Optibrium at a time of significant growth and success as the Company’s technologies drive computer-aided drug discovery across the biotech industry. I look forward to working with a world-class team to develop our innovative platforms, further transforming customers’ drug discovery programmes.”
Edmund Champness, Chief Scientific Officer, Optibrium, said: “We are delighted to welcome Ian to the team to support the scale-up of our infrastructure and technical teams and to lead the development and deployment of our next-generation solutions. Ian brings an impressive combination of experience in cloud engineering, platform development and the pharma industry, which will be invaluable as we continue to expand our computational drug discovery platforms.”
For further information on Optibrium, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.

23 November 2022
Posted by Zyme Communications
Zyme Communications provides PR and marketing services for the life science sector. We support companies to raise their profile, build corporate value and generate interest from commercial leads, investors and partners. …
View profile
Share article

Cambridge Network Limited is a company registered in England under company No. 3400152
The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT
© 2022 Cambridge Network. All Rights Reserved.
Website by KISS


Leave a Comment

Your email address will not be published. Required fields are marked *

Lakers sign Thomas Bryant Tom Brady hint at unretirement this year Kevin Durant trade Warriors stars Brooklyn Nets to sign T.J. Warren ‘Minions’ Fire With $110.5 Million debut